Latest Capital Investments News

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Stealth Group Holdings has reported a record-breaking 2025 financial year, with sales climbing 27.6% and net profit more than doubling. The company is accelerating its growth strategy, aiming to more than double sales by 2028.

Stealth Group Holdings has reported a landmark FY25 with sales soaring 27.6% to $145.1 million and net profit more than doubling. The company’s strategic investments and operational discipline set the stage for ambitious growth targets through FY28.

Karoon Energy has significantly upgraded its Baúna Project 2P Reserves by 35%, extending the field’s economic life by seven years to 2039, driven by the recent FPSO acquisition and improved reservoir performance.

Wagners Holding Company Limited reported a solid FY25 with revenue of $431.3 million, driven by growth in construction materials and composite fibre technologies, while reducing net debt by 29%.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

Propel Funeral Partners has reported record FY25 results, exceeding revenue and EBITDA guidance while maintaining steady dividends and announcing a key executive transition.

Chrysos Corporation reported a robust 46% revenue increase to A$66.1 million for FY25 but faced a significant net loss of A$8.2 million, reflecting rising costs and operational challenges.

IVE Group Limited posted a robust FY25 marked by significant profit growth and margin expansion despite a slight revenue dip, while setting ambitious FY26 targets backed by strategic facility upgrades and sustainability progress.

Kelsian Group reported FY25 results in line with expectations, showing revenue and earnings growth alongside a strategic review that could reshape its business focus. The company also provided FY26 EBITDA guidance and revealed plans to divest its Tourism Portfolio.

Kelsian Group Limited reported a solid 10% increase in revenue for FY25, alongside operational growth and a maintained dividend policy, while advancing sustainability initiatives and strategic portfolio adjustments.